Fidaxomicin (FDX) is a novel antimicrobial agent with narrow-spectrum and potent
bactericidal activity against Clostridium difficile. In recent clinical trials, FDX was superior to …

Clostridioides difficile infection results from a disturbance of the normal microbial flora of the
colon, allowing proliferation of C. difficile and toxin production by toxigenic strains …

This Review summarizes the latest advances in the treatment and prevention of Clostridium
difficile infection (CDI), which is now the most common health-care-associated infection in …

Clostridioides (formerly Clostridium) difficile is responsible for a substantial burden of
nosocomial infection. Recurrent C. difficile infection (rCDI) remains a concern due to its high …

Clostridioides difficile (C. difficile, previously known as Clostridium difficile) infections are a
major health care concern. The Centers for Disease Control and Prevention (CDC) …

Clostridioides difficile is an increasingly common pathogen both within and outside the
hospital and is responsible for a large clinical spectrum from asymptomatic carriage to …

Abstract Recurrent Clostridioides (formerly Clostridium) difficile infection (rCDI) is common,
and patients who have had one recurrence are more likely to have multiple recurrences …

Clostridioides difficile is an urgent public health threat by virtue of being the most common
pathogen in hospitals and an increased risk of community-acquired infection [1]. The …

Until recently, treatment of Clostridium difficile infection (CDI) was mainly limited to oral
metronidazole and vancomycin, neither of which is optimal. Up to 25% of patients with CDI …

Recurrence occurs in approximately 25% of all cases of Clostridium difficile infection (CDI)
and poses a unique clinical challenge. Traditionally, treatment options of CDI have been …